Alzheimer’s disease research developments

Recent neurological research has identified two distinct biological mechanisms that may offer pathways for mitigating Alzheimer’s disease and its associated neurodegeneration.

Researchers at Washington University School of Medicine demonstrated that targeting the immune system can reduce brain damage in tauopathies. By using an antibody to block the CXCR3 protein, scientists were able to prevent T cells from infiltrating the brain. In mouse models, this treatment reduced T cell presence by approximately half and allowed subjects to retain roughly 40% more tissue in memory centers and perform better on memory tests, even without changing tau protein levels. Senior author David M. Holtzman stated that this pathway offers a way to “potentially decrease brain cell death by mitigating the immune system’s response to tau accumulation.”

Separately, researchers at Columbia University identified a mechanism that may explain why some individuals with the high-risk APOE ε4 gene do not develop the disease. Their study suggests that a rare mutation in the fibronectin (FN1) gene protects the blood-brain barrier by limiting the buildup of fibronectin. Because excessive accumulation can damage the barrier and prevent the removal of toxic substances from the brain, researchers suggest that blocking this process could lead to new drug developments.